Table 1.
Characteristics of this study population.
| Characteristics | RA patients |
|---|---|
| (N = 156) | |
| Age, mean (SD), years | 69.7 (6.7) |
| Body composition and physical activity variables | |
| Body mass index, mean (SD), kg/m2 | 22.0 (3.6) |
| Skeletal mass index, mean (SD), kg/m2 | 5.64 (0.83) |
| Handgrip strength-dominant, mean (SD), kg | 14.5 (7.2) |
| Gait speed, mean (SD), m/s | 0.95 (0.29) |
| Sarcopenia (+), n (%) | 70 (44.9) |
| Severe sarcopenia (+), n (%) | 46 (29.5) |
| Any fall in the previous year, n (%) | 25 (16.2) |
| Any fracture in the previous year, n (%) | 7 (4.6) |
| Osteoporosis medication, n (%) | 45 (28.9) |
| MNA-SF, mean (SD) | 12.0 (2.0) |
| RA disease characteristics | |
| Duration, mean (SD), years | 16.1 (12.7) |
| DAS28-ESR, mean (SD) | 2.96 (0.98) |
| HAQ score, mean (SD) | 0.83 (0.74) |
| Stage*, mean (SD) | 3.01 (1.10) |
| Stage 1, n (%) | 21 (13.4) |
| Stage 2, n (%) | 29 (18.6) |
| Stage 3, n (%) | 33 (21.1) |
| Stage 4, n (%) | 73 (46.8) |
| Class*, mean (SD) | 1.82 (0.60) |
| Current RA medications | |
| Methotrexate use, n (%) | 105 (67.3) |
| Prednisolone use, n (%) | 43 (27.6) |
| Biological agent use, n (%) | 55 (35.3) |
| Laboratory data | |
| Serum 25(OH)D, median (IQR), ng/ml | 16.0 (12.8–19.2) |
| CRP, median (IQR), mg/dL | 0.1 (0.075–0.30) |
Data are presented as the mean (standard deviation (SD)) or as the median (interquartile range (IQR)) for continuous variables, and as numbers (%) for categorial variables.
RA rheumatoid arthritis, MNA-SF Mini Nutritional Assessment Short-Form, DAS28 disease activity score using 28 joints, VAS visual analogue scale, HAQ health assessment questionnaire.
*Steinbrocker's classification.